

Human Leukocyte Antigen Class I-Restricted Activation of CD8⁺ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity

Diana Chessman, Lyudmila Kostenko, Tessa Lethborg, Anthony W. Purcell, Nicholas A. Williamson, Zhenjun Chen, Lars Kjer-Nielsen, Nicole A. Mifsud, Brian D. Tait, Rhonda Holdsworth, Coral Ann Almeida, David Nolan, Whitney A. Macdonald, Julia K. Archbold, Anthony D. Kellerher, Debbie Marriott, Simon Mallal, Mandvi Bharadwaj, Jamie Rossjohn,* and James McCluskey*

*Correspondence: jamie.rossjohn@med.monash.edu.au (J.R.), jamesm1@unimelb.edu.au (J.M.)

DOI 10.1016/j.immuni.2008.06.002

(Immunity 28, 822–832, June 2008)

In [Figure 5](#) of this paper, the FACS events (dots) were inadvertently lost in the right-hand panel (panel 4, B*57 116 Ser-Tyr) during the preparation of the revised manuscript. The complete [Figure 5](#) is reproduced here. The authors regret this error.




Figure 5. Fine Specificity of Abacavir-Specific CD8⁺ T Cells Determined by the Antigen-Binding F Pocket

Abacavir-specific T cells were raised in vitro from a HLA-B*5701-positive donor and then restimulated with the C1R cell lines expressing HLA-B*5701, HLAB*5703, the HLA-B*5703 back mutant 114Asp→Asn, or the HLA-B*5703 back mutant 116Ser→Tyr. Flow histograms of gated lymphocytes are shown stained for intracellular IFN γ (y axis) and CD8 (x axis). The percentage of responding IFN γ ⁺ CD8⁺ T cells as a fraction of total gated lymphocytes is shown in the upper-right-hand quadrants. Differences between the peptide-binding clefts of HLA-B*5701, HLA-B*5703, and HLA-B*5703 back mutants are indicated with filled circles, and the amino acid substitutions from B*5701 are given above each illustration.